ICH E14/S7B: When Concentration-QTc Modeling Replaces the TQT Study

For a decade after ICH E14 took effect in 2005, a dedicated thorough QT (TQT) study was close to mandatory: a standalone trial, often in healthy volunteers, built solely to rule out drug-induced QTc prolongation before a compound could move through late-stage development. A December 2015 Q&A revision changed that by name, allowing concentration-QTc (C-QTc) modeling from ordinary Phase I data to stand in for the TQT study. Most sponsors know the TQT study is no longer automatic. Fewer have built the exposure-response design, or the 2022 nonclinical risk assessment that now accompanies it, that actually earns the waiver.

What the 2015 Q&A actually changed

The original ICH E14 guidance treated the TQT study as the primary evidence for cardiac safety, with Phase I and later clinical ECG data serving a secondary, confirmatory role. The December 2015 Q&A revision inverted that hierarchy for compounds with the right data: a concentration-QTc analysis built from the ECG and pharmacokinetic data already collected in routine single- and multiple-ascending-dose studies could serve as the primary evidence instead, with no separate TQT trial run at all. The guidance also dropped a specific procedural burden — where exposure-response data already characterize drug effect at a sufficiently high multiple of the clinical dose, a dedicated positive control arm is not required to validate assay sensitivity, because the C-QTc model itself demonstrates the study could detect an effect if one existed.

Why the exposure margin is the whole argument

A C-QTc analysis is not a lighter-touch version of a TQT study; it is a different kind of evidence that has to do the same job. The model needs ECG and concentration data spanning a range wide enough to characterize the drug's effect at a clinically relevant supratherapeutic exposure — not just the expected therapeutic range — with confidence intervals tight enough to rule out a mean QTc effect of regulatory concern at that margin. A Phase I IND application program designed around minimum-viable dosing and a narrow safety margin will not generate the exposure spread the analysis needs; retrofitting a wider dose range after the fact means a second study, which is the outcome the waiver was supposed to avoid.

• Exposure range, not just dose range. The analysis has to characterize effect at supratherapeutic plasma concentrations, which means the SAD/MAD design has to reach those concentrations safely — a dosing decision made months before any QTc data exist.
• Model pre-specification. Reviewers expect the concentration-QTc relationship, the covariates, and the precision threshold defined before the data are analyzed, not selected afterward from among several models that happen to pass.
• ECG acquisition quality. Digital, time-matched ECG collection at the same timepoints as PK sampling is what makes the model credible; sparse or mistimed ECGs undermine the analysis regardless of the modeling approach.
• Sponsor engagement timing. Sponsors who raise the C-QTc strategy at an early FDA meeting, rather than defending it after the Phase I data are already collected, get far more design input into the sampling scheme that makes the waiver viable.

A concentration-QTc analysis earns its place as primary evidence. It does not inherit the TQT study's presumption of adequacy just because the agency now accepts it as an alternative. Why the waiver is a design decision, not a filing choice

The 2022 update: nonclinical and clinical as one risk assessment

The August 2022 ICH E14/S7B Q&A did not replace the 2015 clinical framework; it wrapped a nonclinical risk assessment around it. The update added new S7B questions — covering best-practice in vitro ion-channel studies, in vivo nonclinical proarrhythmia models, and how to weigh them together — alongside revised E14 questions describing how that nonclinical evidence should inform the interpretation of a borderline or ambiguous clinical C-QTc result. The practical effect is that a nonclinical development program built for its own sake, with ion-channel and in vivo cardiovascular safety studies scoped independently of the clinical cardiac-safety plan, no longer produces a package that reads as integrated evidence. Reviewers now expect one risk narrative, not two guidance-shaped deliverables stapled together.

None of this requires abandoning the TQT study option — for some mechanisms, particularly those with a plausible direct ion-channel interaction or a narrow therapeutic index, a dedicated study is still the more defensible path. The decision point is early: whether the Phase I program is built to generate C-QTc-grade exposure-response data by design, or discovers after the fact that it cannot support the waiver it was hoping to claim. Sponsors who treat the exposure margin and the nonclinical risk assessment as Phase I design inputs — not Phase I outputs to be interpreted later — are the ones who reach the clinical plan without a surprise second cardiac-safety study on the critical path.